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Abstract: Hereditary angioedema (HAE) caused by C1-esterase inhib-
itor deficiency is an autosomal-dominant disease resulting from a
mutation in the C1-inhibitor gene. HAE is characterized by recurrent
attacks of intense, massive, localized subcutaneous edema involving the
extremities, genitalia, face, or trunk, or submucosal edema of upper
airway or bowels. These symptoms may be disabling, have a dramatic
impact on quality of life, and can be life-threatening when affecting the
upper airways. Because the manifestations and severity of HAE are
highly variable and unpredictable, patients need individualized care to
reduce the burden of HAE on daily life. Although effective therapy for
the treatment of HAE attacks has been available in many countries for
more than 30 years, until recently, there were no agents approved in the
United States to treat HAE acutely. Therefore, prophylactic therapy is
an integral part of HAE treatment in the United States and for selected
patients worldwide. Routine long-term prophylaxis with either attenu-
ated androgens or C1-esterase inhibitor has been shown to reduce the
frequency and severity of HAE attacks. Therapy with attenuated an-
drogens, a mainstay of treatment in the past, has been marked by
concern about potential adverse effects. C1-esterase inhibitor works
directly on the complement and contact plasma cascades to reduce
bradykinin release, which is the primary pathologic mechanism in
HAE. Different approaches to long-term prophylactic therapy can be
used to successfully manage HAE when tailored to meet the needs of
the individual patient.
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Hereditary angioedema (HAE) caused by C1-esterase in-hibitor deficiency is an autosomal-dominant disease re-
sulting from a mutation in the C1-inhibitor gene.1,2 Although
HAE is an inherited disorder, 25% of cases arise from
spontaneous mutations.3 HAE is characterized by recurrent
attacks of intense, massive, localized subcutaneous edema,
without pruritus, involving the extremities, genitalia, face, or
trunk, or submucosal edema of the upper airway or bowels.2,4
There is a scarcity of epidemiologic studies on HAE preva-
lence. Studies based on national HAE registries show a
minimal prevalence ranging from 1.09 to 1.51 in 100,000
inhabitants,5–7 with the actual prevalence expected to be
higher. Estimates indicate that approximately 1 in 50,000
people in the general population has HAE.8 No sex or race
predominance has been described.3
Mutations in the C1-inhibitor gene located on chromo-
some 11 cause 2 major forms of HAE: type I and type II.9 In
type I HAE, which accounts for approximately 85% of HAE
cases, low C1-esterase inhibitor levels result from a deficiency in
the amount of C1-esterase inhibitor produced. Both functional
and antigenic C1-esterase inhibitor levels are reduced.10,11 Type
II HAE accounts for 15% of cases and is characterized by
normal or elevated antigenic C1-esterase inhibitor with low
levels of functional C1-esterase inhibitor.2,12,13 The 2 types of
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HAE are alike in clinical presentation, but are caused by differ-
ent mutations. According to the C1-inhibitor gene mutation
database, more than 275 different mutations have been identi-
fied.14 Most mutations are small deletions, insertions, or point
mutations, however, larger rearrangements of the gene with
partial duplications or deletions account for 15 to 20% of all
mutations leading to HAE.13,15–17
A rare third type of HAE does not exhibit a deficiency
in C1-esterase inhibitor.18,19 HAE with normal C1-esterase
inhibitor may be associated with mutations in the coagulation
factor XII gene but there are patients who do not exhibit any
genetic mutations.18,20 This communication restricts the dis-
cussion to the type I and type II HAE caused by deficiency of
functional C1-esterase inhibitor.
To review the current status of prophylactic manage-
ment of HAE, an international panel of experts was assem-
bled in Philadelphia, PA, on August 13–14, 2010. Because of
different approaches to management of HAE in various
countries, these proceedings attempt to reflect the spectrum of
prophylaxis treatment options with a focus on androgen and
C1-esterase inhibitor therapy.
CLINICAL PRESENTATION
The symptoms of both type I and type II HAE are
indistinguishable. Although the initial symptoms of HAE can
occur at any age, symptoms usually first appear in childhood,
worsen during puberty, and persist throughout life, with
attack frequency and severity varying from patient to patient.
HAE is not generally diagnosed at initial presentation, and
the time of diagnosis has been shown to range from 8 to 22
years from the first attack.6,21,22 Attacks often occur without
a trigger; however, precipitating factors that have been
shown to contribute to the frequency of attacks include stress,
trauma, infection, menstruation, and pregnancy.3,4,9,21,23 Vari-
ous medications, such as estrogen-containing agents and
angiotensin-converting enzyme inhibitors, may also induce
HAE attacks.3,4,9,21,23 Before attacks, many patients experi-
ence prodromal symptoms that can include tingling sensa-
tions or erythema marginatum, a nonpruritic and not raised
rash (Fig. 1).4,21,24 The patient’s family history or frequency and
severity of attacks do not predict the course of future attacks nor
do they predict involvement of the airway during an attack.25
The cardinal symptoms of HAE include episodic, local-
ized, nonurticarial, nonpitting subcutaneous edema of the skin
(hands, arms, legs, feet, trunk, face, genitalia) and submucosal
edema of the bowels and upper airway.2–4,9 Attacks may affect
several sites of the body simultaneously or consecutively.
Edema typically progresses slowly, peaks over the first 24 to 36
hours, and usually resolves within 72 hours, but can persist for
as long as 1 week. HAE attacks can be painful and disfiguring
but are usually not life-threatening. Attacks affecting the upper
airways, however, can lead to obstruction and suffocation, and
the manifestations of gastrointestinal edema (ie, abdominal at-
tacks) can include intractable abdominal pain, vomiting, nausea,
diarrhea, and intestinal obstruction, and potentially can lead to
hypovolemic shock.2–4,9,26,27
During an attack, the activation of the complement and
contact cascades and the inadequate response by C1-esterase
inhibitor cause an overproduction of bradykinin (Fig. 2).2
Increased bradykinin levels increase vascular permeability
and extravasation, manifesting as edema (Fig. 2).1,28–30 This
is an important differentiating feature of HAE when com-
pared with allergic reactions, which are primarily mediated
by histamine. During an allergic reaction, IgE antibodies
react with specific allergens, inducing histamine release from
mast cells.9 This reaction leads to angioedema and/or urti-
caria, which subside with use of epinephrine, antihistamines,
or corticosteroids. In contrast, HAE manifestations do not
respond to such therapies because symptoms and swelling are
mediated by bradykinin.9
CONSEQUENCES
The consequences of HAE are considerable. HAE may
account for 15,000 to 30,000 emergency department visits an-
nually in the United States alone.31,32 Laryngeal edema presents
the greatest risk to patients, and approximately 50% of patients
with HAE have at least 1 laryngeal attack in their lifetime.9 In
the past, fatality from asphyxiation during a laryngeal attack was
reported in approximately 30% of patients with HAE.9 Fatal
laryngeal attacks still may occur, particularly in the absence of a
proper diagnosis or in patients who do not receive appropriate or
timely treatment.2,33 Patients with HAE are often misdiagnosed,
resulting in unnecessary medical and surgical interven-
tions.22,31,34 Abdominal symptoms may mimic an acute appen-
dicitis or other forms of acute abdomen and lead to unnecessary
abdominal surgery.2,8,22 According to 1 estimate, 45% of pa-
tients presenting to an emergency department with an HAE
attack are subsequently hospitalized.35
The symptoms of HAE may be disabling and have a
dramatic impact on quality of life.36 Swelling in the hands
and feet can be debilitating, abdominal attacks often cause
extreme pain, and facial attacks are generally disfiguring and
may extend to involve the larynx.21 HAE attacks typically
FIGURE 1. Erythema marginatum on the arm of a patient
with hereditary angioedema. Note that lesions are neither
raised nor pruritic. Photography courtesy of William R.
Lumry, MD.
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incapacitate patients for 20 to 100 days annually depending
on attack severity, frequency, and duration.13 HAE signifi-
cantly impacts the ability of a patient to work or go to school;
these impairments are comparable to those experienced by
patients with severe asthma or Crohn’s disease.36 Patients
may develop narcotic dependence while trying to appropri-
ately manage frequent and severe abdominal pain.37 Addi-
tional care may be required to manage the psychologic impact
of HAE disease.37 Patients with HAE are more likely to suffer
symptoms of depression than the general population, with
42.5% of patients showing at least mild symptoms of depres-
sion.36 Data suggest that patients with more severe disease are
more likely to experience depression than those with mild or
infrequent attacks.36 Patients with HAE are nearly twice as
likely to report taking psychotropic or antidepressant medi-
cation compared with the general population.36
DIAGNOSIS
Identifying HAE may be difficult because of variability
in clinical presentation. HAE should be suspected in patients
presenting with any of the characteristic symptoms, espe-
cially in the presence of a positive family history.25 Screening
for genetic mutations is not generally performed for diagnos-
tic reasons. Instead, laboratory testing is indicated for patients
with suspected HAE. Biochemical markers used for the
diagnosis of HAE are serum complement factor 4 (C4),
C1-esterase inhibitor antigen, functional C1-esterase inhibi-
tor, and C1q antigenic protein.25 The most cost-effective
method to screen for HAE is measurement of C4 levels.2 If
C4 is normal, as can occur in some patients between attacks,
the measurement should be repeated during an acute attack.25
Whether to obtain C1-esterase inhibitor antigen and func-
tional C1-esterase inhibitor studies at the time of C4 collec-
tion or at a subsequent time can be based on the index of
suspicion. Low levels of C4, C1-esterase inhibitor antigenic
protein, and functional C1-esterase inhibitor are consistent
with a type I HAE diagnosis but should be confirmed via a
second measurement. Low levels of C4 and functional C1-
esterase inhibitor with normal or elevated C1-esterase inhib-
itor antigenic protein are indicative of type II HAE.25 C1q
antigenic protein is normal in HAE.25 It should be noted that
variability in symptoms is not related to the levels of biochem-
ical markers and that patients with lower levels of the markers
outlined here do not necessarily exhibit more severe HAE
symptoms than those with higher levels.2 A recent study, how-
ever, found a significant correlation between severity scores and
baseline functional C1-esterase inhibitor levels, which suggests
the potential significance of monitoring functional C1-esterase
levels in relation to clinical disease course.38
TREATMENT APPROACHES
The goals of treatment for HAE are focused on life-saving
efforts, slowing the progression and severity of attacks, and
reducing the number of attacks and their impact on patient
quality of life. Because of large variations in clinical presenta-
FIGURE 2. Pathways inhibited
by C1-esterase inhibitor (C1INH)
(reproduced from Zuraw,2 with
permission).
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tion and severity of disease, HAE treatment is individualized and
based on a close collaboration between physician and patient.
The pharmacotherapy of HAE can be categorized into
3 approaches: acute treatment, short-term prophylaxis, and
long-term prophylaxis. Acute treatment options for HAE
include C1-esterase inhibitor (human or recombinant) replace-
ment therapy, icatibant, or ecallantide (Table 1)2,9,25,39–48; how-
ever, it should be noted that not all agents are currently approved
in all countries. Infusions of C1-esterase inhibitor concentrate
have been shown to increase functional levels of C1-esterase
inhibitor and C4 to near-normal levels.49 Icatibant is a bradyki-
nin B2-receptor antagonist that reverses increased vascular per-
meability and inhibits vasodilation and extravasation.40 Ecallan-
tide is a human plasma kallikrein inhibitor that treats HAE
symptoms by directly inhibiting plasma kallikrein and decreas-
ing the conversion of high-molecular-weight kininogen to bra-
dykinin.41 Fresh frozen plasma has been used, but its utility is
limited because it contains additional kinins and complement
factors, posing a potential threat of worsening HAE symp-
toms.3,34 Nevertheless, successful use of fresh frozen plasma has
been reported for both acute treatment and prophylaxis.50–52
HAE is mediated by bradykinin, therefore, it is noteworthy to
mention that treatments used for other forms of angioedema,
including antihistamines, epinephrine, and corticosteroids, are
ineffective in treating HAE-related angioedema and should be
avoided.4
The goal of short-term, or procedural, prophylaxis is to
prevent an HAE attack in patients that may be triggered by
medical, surgical, or dental procedures.4,53 C1-esterase inhib-
itor, attenuated androgens, antifibrinolytics, icatibant, and
fresh frozen plasma have been used successfully for short-
term prophylaxis.2,8,25,54 Consensus guidelines recommend
that patients with HAE receive prophylactic treatment with
500 to 1,500 U of C1-esterase inhibitor 1 to 6 hours before
the procedure.25 If C1-esterase inhibitor is not available, the
guidelines recommend treatment with an attenuated androgen
for 5 days before the procedure and 2 to 5 days after, or
administration of fresh frozen plasma 1 to 6 hours before the
procedure.25
Although effective therapy for the treatment of HAE
attacks has been available in many countries for more than
30 years, until recently, there were no agents approved in the
United States to treat HAE acutely. Therefore, prophylactic
therapy is an integral part of HAE treatment in the United
States and for selected patients worldwide. Long-term, or rou-
tine, prophylaxis is an important treatment option for patients
with HAE. Patients who can be considered for prophylactic
therapy are those who experience frequent or severe attacks,
have had a previous laryngeal attack, have significant anxiety
and poor quality of life as a result of HAE, have limited access
to emergency medical care, or choose to receive prophylaxis.37
In addition, long-term prophylaxis is indicated in patients for
whom acute therapy is ineffective or unavailable.37 Attenuated
(17-alpha alkylated) androgens have long been the gold standard
for prophylaxis in numerous countries, with danazol, stanazolol,
and oxandrolone being used more frequently than other andro-
gens. Although the precise mechanism of action is not known,
attenuated androgens are thought to increase endogenous C1-
esterase inhibitor levels via hepatic synthesis and a subsequent
increase in the expression of mRNA.55,56
Another long-term prophylaxis treatment option, recently
approved for use in the United States, is nanofiltered human
C1-esterase inhibitor concentrate.43 The antifibrinolytic agents,
-aminocaproic acid and tranexamic acid, are not approved in
the United States but have been used extensively in some
European countries for long-term prophylaxis, especially in
children and pregnant women in whom androgen therapy is
contraindicated because of significant risk of adverse ef-
fects.4,8,37 Antifibrinolytics may also be useful in other patients
in whom attenuated androgens or intravenous therapy is not
TABLE 1. Drugs Commonly Used for Acute and Prophylactic Treatment of HAE2,9,25,45–48
Drug Class or Name
Adult Dosage and Route of




20 U/kg IV Replaces missing or malfunctioning C1-esterase inhibitor
Ecallantide 30 mg SC split into 3 injections Potent, selective, reversible inhibitor of plasma kallikrein, which reduces the
conversion of high–molecular-weight kininogen to bradykinin




Exact mechanism not known. Thought to increase endogenous C1-esterase
inhibitor levels via hepatic synthesis and a subsequent increase in the
expression of mRNADanazol 100 mg PO every 3 days to 600 mg QD
Oxandrolone 2.5 mg PO every 3 days to 20 mg QD
Stanozolol 1 mg PO every 3 days to 6 mg QD
Antifibrinolytics Inhibit the formation and activity of plasmin and subsequently decrease
plasmin-induced activation of C1Tranexamic acid 20–50 mg/kg/d PO split BID or TID
-aminocaproic acid 8 to 12 g PO daily in 4 divided doses
Nanofiltered C1-esterase
inhibitor (human)
1000 U IV every 3 to 4 days Replaces missing or malfunctioning C1-esterase inhibitor
BID, twice daily; HAE, hereditary angioedema; IV, intravenous; PO, by mouth; QD, once daily; SC, subcutaneous; TID, 3 times daily; U, units.
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appropriate. However, because of relatively low efficacy and
poor safety profile, including the potential to cause hypotension,
cardiac arrhythmias, rhabdomyolysis, and thromboembolism,
the use of antifibrinolytics is limited.2,9,41,57
Attenuated androgens and C1-esterase inhibitor are at
the forefront of long-term prophylaxis therapy options for
HAE, and therefore the goal of this paper is to provide an
overview of the literature and clinical experience with these
agents and identify patients who are candidates for each type
of treatment. A discussion of other therapies is beyond the
scope of this paper.
EXPERIENCE WITH ATTENUATED ANDROGEN
THERAPY IN THE LONG-TERM PROPHYLAXIS
OF HAE
Attenuated androgen therapy is the most commonly
prescribed prophylactic therapy and most extensively studied,
largely because until recently, it was the only approved
prophylaxis treatment option for HAE in the United States.58
Danazol, stanozolol, and oxandrolone are the attenuated an-
drogens typically used as prophylaxis for HAE.37 Data dem-
onstrate that approximately 94 to 100% of patients respond to
prophylactic therapy with danazol and report a decrease in
frequency and severity of attacks; however, 5 to 8% of
patients do not respond to danazol therapy (Fig. 3).59–62
Although danazol is effective in reducing the number of
attacks, the majority of patients treated with this agent are not
symptom-free. In a large retrospective study, 24% of patients
were symptom-free while taking danazol, whereas approxi-
mately 14% who responded to danazol therapy had 11 or
more attacks per year.59 Recent data suggest that long-term
use of this agent may result in reduced efficacy over time.
Reports indicate that in some patients the effect of danazol
declines after 4 to 6 years of treatment.59,63–65 Although
attenuated androgens are not approved therapy for HAE in
children, danazol has been shown to be effective prophylactic
therapy in prepubescent children with severe recurrent HAE
attacks.64,66 Stanozolol and oxandrolone are preferred by
some clinicians for use in children partly because of their
improved safety profiles.2,67,68 Therapy in children is compli-
cated by the potential for androgens to affect growth and
development, particularly premature closure of epiphyseal
plates resulting in decreased growth.2,64 In all patients, atten-
uated androgen dosing should be individualized and based on
clinical response.2,25 Furthermore, caution should be exer-
cised when switching agents because no dose-equivalency
data currently exist.
Attenuated androgens pose a significant risk for adverse
events, leading some patients to refuse therapy. Side effects
may include weight gain, acne, virilization, altered libido,
menstrual irregularities, headaches, depression, fatigue, lipid
abnormalities, hypertension, cholestasis, increased liver en-
zymes, peliosis hepatitis, and hepatocellular adenomas.2,8,59,69–73
To review the published safety data on these agents, we per-
formed a literature search and identified articles that included an
evaluation of the safety of long-term attenuated androgen ther-
apy in HAE (Table 2).59–62,70,72–76 We found that many patients
experience adverse effects while taking attenuated andro-
gens.59,62,72,77,78 These adverse effects can be controlled or min-
imized by using the lowest effective dose, and some patients are
capable of tolerating the adverse effects associated with attenu-
ated androgen therapy. It should be noted, however, that many
of the patients in these reports were treated with attenuated
androgens at a time when there were very limited options for
prophylactic therapy for HAE.
Patient compliance with attenuated androgen therapy
may be affected by considerable weight gain, the amount of
which has been reported to be as high as 45 kg in 1 patient
after receiving 1 year of therapy with danazol 800 mg daily.59
Affecting women in particular, virilization symptoms such as
voice changes, hirsutism, decrease in breast size, clitoral
hypertrophy, increase in muscle mass, disturbances in libido,
and laryngeal prominence have been reported with varying
ranges of frequency and severity.58,59,72,74 Although some
studies demonstrate a prevalence rate of approximately 2%,60
symptoms of virilization have been reported to occur in as
many as 1 in 3 patients72 and in up to 79% of female patients
receiving attenuated androgens.74 Acne resulting from atten-
uated androgen therapy also can be a significant source of
anxiety among patients. Because of the risk of causing tera-
FIGURE 3. Reduction rate of HAE attacks during long-term
treatment with danazol in 118 patients (reproduced from
Bork et al,59 with permission).





Weight gain 14.3–60.0 59, 60, 62, 70, 72, 74, 75
Acne 4.8–22.0 59, 62, 70, 72, 75, 76
Virilization† 1.8–46.6 59, 60, 62, 72, 75
Menstrual irregularities 14.4–80.0 59–62, 70, 72, 75, 76
Headache/migraine 13.6–49.5 59, 62, 74, 75
Psychological abnormalities‡ 9.4–16.0 59, 62, 72
Arterial hypertension 25.0–30.0 70, 74
Lipid abnormalities 27.0 73, 75
Hepatic disease/adenomas§ 1.8–40.0 59, 60, 62, 75
Hematuria 13.0 62
*Includes data for danazol and stanozolol. Patients may have experienced more
than 1 adverse event.
†Includes voice changes, increased hair growth, decrease in breast size, clitoral
hypertrophy, increase in muscle mass, laryngeal prominence.
‡Includes depression, aggressiveness, fatigue, panic attacks, mood changes.
§Includes increase in pathological laboratory findings, including hepatic enzymes.
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togenic effects in an unborn fetus, in particular masculiniza-
tion, nonhormonal contraception or progestin-only birth con-
trol pills are recommended in fertile female patients taking
attenuated androgens.79 Many female patients also report
menstrual irregularities such as menometrorrhagia or amen-
orrhea while receiving attenuated androgen therapy.60,75 In
male patients, loss of libido and gynecomastia have been
known to occur with androgen use.58
Other undesirable effects of androgens include headache,
migraine, and alopecia.59,62,74,75 Psychologic abnormalities such
as anxiety, depression, aggressiveness, fatigue, panic attacks,
and mood changes have been reported to occur in as many as
16% of patients receiving attenuated androgen therapy.59,62
Additional serious adverse effects such as hypertension,
lipid abnormalities, cystitis, hematuria, and liver disease, includ-
ing adenomas and carcinoma, have also been associated with
attenuated androgen therapy.59,60,62,70,73–75,80,81 In 1 study, pa-
tients who received long-term prophylaxis for HAE with dana-
zol were at a higher risk for developing abnormally low levels of
high-density lipoprotein and high levels of low-density lipopro-
tein when compared with patients not taking attenuated andro-
gens and healthy control subjects.73 Liver disease, ranging from
increased transaminases to adenomas and peliolosis hepatitis,
has been reported with androgen use and warrants vigilant
monitoring of liver function.59,60,62,75,82 According to the Inter-
national Consensus Algorithm for the Diagnosis, Therapy, and
Management of Hereditary Angioedema,25 patients receiving
attenuated androgens should be monitored every 6 months for
changes in liver function (ie, alanine aminotransferase [ALT]/
aspartate aminotransferase [AST], alkaline phosphatase), lipid
profile, complete blood cell count, and urinalysis. Patients re-
ceiving more than 200 mg of danazol daily and patients who are
of prepubescent age should undergo an ultrasound of the liver
and spleen every 6 months and a yearly alpha fetoprotein level.
Patients receiving less than 200 mg of danazol daily should
undergo an ultrasound of the liver and spleen on a yearly
basis.25,83
The side effects associated with attenuated androgens
may lead patients to discontinue therapy. In a large series of
patients with HAE who were treated with prophylactic dana-
zol from 2 months to 30 years, more than 25% discontinued
danazol because of adverse effects and almost 10% discon-
tinued because of a fear of adverse effects.59 One half of
patients who discontinued danazol as a result of adverse
effects did so within the first 2 years of therapy. Also, the
average dose of danazol was higher in patients who discon-
tinued because of adverse effects than in patients who reported
side effects but continued therapy (254 mg/d vs 154 mg/d,
respectively). The side effects associated with attenuated andro-
gens seem to be dose dependent and increase with duration of
therapy.58 This underscores the importance of titrating to the
lowest dose that confers adequate prophylaxis to avoid or at least
mitigate adverse effects.2,78
EXPERIENCE WITH C1-ESTERASE INHIBITOR IN
THE LONG-TERM PROPHYLAXIS OF HAE
The first large-scale attempt to purify C1-esterase in-
hibitor was documented in 1974.84 The development of im-
proved manufacturing processes resulting in purified human
plasma-derived C1-esterase inhibitor formulations has en-
abled their use for the treatment of HAE attacks since the
1980s.85 C1-esterase inhibitor is also highly effective in
patients requiring short-term prophylaxis85–88 and its utility
has been confirmed in patients with frequent attacks who
experience intolerance to or lack of efficacy with danazol
therapy.89,90 However, experience with C1-esterase inhibitor
in long-term prophylactic therapy is not as extensive as for
acute treatment or short-term prophylaxis; long-term prophy-
laxis was not explored until 1989 and efficacy in a controlled
trial was not confirmed until 1996.49,91 Studies with earlier
C1-esterase inhibitor formulations have shown a reduction in
the frequency of attacks in patients with HAE.92 In 1 study,
more than 75% of patients were almost asymptomatic while
receiving bolus intravenous (IV) injections of C1-esterase
inhibitor 2 to 3 times weekly.93 In a more recent study, 19
patients with HAE underwent weekly long-term therapy with
C1-esterase inhibitor for an average of 9 years.94 Disease
severity was significantly improved by 1 or more injections of
C1-esterase inhibitor per week; the percentage of severe
attacks was 93.3% without and 3.8% with treatment.94 To
achieve this reduction in severity, patients were willing to
accept 1 or more weekly IV injections. Although the majority
of patients had fewer attacks during the last 12 months of the
study, approximately one third reported more attacks. Signs
of increasing disease activity (eg, multilocular edema) were
reported in several patients, but no causal link was demon-
strated in this observational study.
Efficacy data for the nanofiltered C1-esterase inhibitor
approved for prophylactic therapy demonstrate an approxi-
mate 50% reduction in average normalized attack rates com-
pared with placebo when administered over two, 12-week
crossover periods (6.26 vs 12.73 attacks for C1-esterase
inhibitor and placebo, respectively; difference 6.47 [95%
confidence interval 4.21, 8.73]; P  0.001).43 In the same
study, prophylaxis with C1-esterase inhibitor demonstrated
significantly lower severity of attacks (1.3  0.85 vs 1.9 
0.36, P  0.001) and significantly shorter duration of attacks
(2.1  1.13 vs 3.4  1.39 days, P  0.002) when compared
with placebo, respectively.43 Recent data from an open-label
trial confirm this finding. Patients enrolled in the study had a
decrease in the median number of HAE attacks from 3.0 per
month to 0.2 per month, and 86% of patients had 1 attacks
per month.95
The selection of a C1-esterase inhibitor over other
prophylactic therapy options is a choice made as a result of
consultation between physician and patient; the focus is on
treatment failure or intolerance to other regimens or the
inability to receive other prophylactic treatment options be-
cause of contraindications.37 Similar to all drug therapies,
C1-esterase inhibitor products also have safety concerns. In a
clinical trial evaluating the use of 1 C1-esterase inhibitor
(Berinert, CSL-Behring, King of Prussia, PA) in HAE at-
tacks, the following adverse events were observed: headache,
abdominal pain, nausea, muscle spasms, pain, diarrhea, and
vomiting.42 The safety results of a study evaluating the efficacy
of nanofiltered human C1-esterase inhibitor (CINRYZE, Viro-
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Pharma Inc, Exton, PA) in prophylactic therapy show the
most common adverse events to be sinusitis, rash, headache,
and upper respiratory infection, irrespective of causality
(Table 3).46 In the opinion of the investigators, the only
adverse events that were possibly or definitely related to this
C1-esterase inhibitor were pruritus and rash, lightheadedness,
and fever.43 In an open-label study, the adverse events most
frequently related to nanofiltered C1-esterase inhibitor were
headache (5.5%), nausea (4.1%), rash (2.7%), erythema
(2.1%), and diarrhea (2.1%). The risk of experiencing a
hypersensitivity reaction to the nanofiltered C1-esterase in-
hibitor is low.95 An increased risk for thrombotic events was
seen in preclinical animal studies and in neonates undergoing
cardiovascular surgery from off-label use of extremely high
doses of C1-esterase inhibitor therapy.96,97 Studies conducted
in humans show that a dose of up to 100 U/kg does not lead
to thrombotic events.98,99 Nevertheless, thrombotic events
have been reported with C1-esterase inhibitors; patients who
are at risk for thrombosis should be monitored while on
C1-esterase inhibitor therapy. It is noteworthy to mention that
discontinuation resulting from an adverse event associated
with nanofiltered human C1-esterase inhibitor is rare; in a
recently completed open-label study, no patient discontinued
study therapy because of an adverse event.95
Commercially available C1-esterase inhibitor products
are derived from human blood and theoretically carry the risk
of viral transmission (eg, parvovirus B19, hepatitis B, hepa-
titis C, and human immunodeficiency virus). Initial develop-
ment of human plasma-derived C1-esterase inhibitor was
complicated by the need for purification steps to reduce the
transmission of viral diseases. Viral inactivation and removal
steps in the production of C1-esterase inhibitor were intro-
duced in the mid-1980s.85 The approval of Berinert-P (CSL
Behring GmbH, Marburg, Germany; C1-esterase inhibitor,
human) in Europe in 1985 brought to market a formulation
that used numerous steps to reduce viral transmission, includ-
ing careful donor screening and viral contaminant elimination
and inactivation through adsorption, precipitation, and pas-
teurization steps.92,100 More recently, manufacturing of an-
other C1-esterase inhibitor formulation has incorporated a
nanofiltration step through 2 serial 15-nm filters to reduce
transmission of enveloped and nonenveloped viruses and
possibly prions.43,101 It is important to note that, as a result of
these purification measures, no cases of virus transmission
have been attributed to the purified preparations of C1-
esterase inhibitor currently available.42,46,87,95,100,102
CLINICAL EXPERIENCE DISCUSSION
The manifestations and severity of HAE are highly
variable and unpredictable, which necessitates individualized
therapeutic approaches. Worldwide, a variety of treatment
options are used to manage the disease. On-demand therapy
for attacks with C1-esterase inhibitor is sometimes used as a
patient’s sole method of treatment or it may be used to treat
breakthrough attacks in patients who are taking long-term
prophylaxis.103 Home therapy refers to treatment given by the
patient (self-administration) or a trained caregiver outside of
a healthcare facility. On-demand home therapy with C1-
esterase inhibitor has proven successful in selected patients
and offers patients the possibility of earlier treatment and
better symptom control103–106; however, this use is not cur-
rently approved in the United States. For prophylaxis, oral
attenuated androgens or IV C1-esterase inhibitor are at the
forefront. Home therapy is only approved with the nanofil-
tered C1-esterase inhibitor that is approved for routine pro-
phylaxis against angioedema attacks in adolescents and adults
in the United States.46
Undoubtedly, clinicians must take into consideration
the benefits and risks of an agent when evaluating treatment
options for long-term prophylaxis of HAE. This should in-
clude a careful assessment of treatment impact on patient
quality of life. One study conducted by Kreuz and col-
leagues89 demonstrated that patients with severe HAE who
discontinued long-term prophylaxis with danazol because of
lack of efficacy, intolerability, or severe side effects had a
significant improvement in quality-of-life scores after receiv-
ing C1-esterase-inhibitor therapy (Fig. 4).89 Although these
results should not be generalized to the larger HAE popula-
tion because the enrolled patients were refractory to danazol
therapy, they emphasize the negative impact that lack of
efficacy or adverse effects can have on patients. Here we
discuss our clinical experience with attenuated androgens and
C1-esterase inhibitor and their appropriateness for long-term
prophylactic use on a case-by-case basis.
CASE 1: LONG-TERM PROPHYLAXIS WITH
C1-ESTERASE INHIBITOR
A 10-year-old girl presented to the emergency depart-
ment (ED; case provided by Dr William Lumry, USA)
complaining of inability to swallow. Her symptoms began
2 hours before arrival. She reported awakening with a feeling
of fullness in her throat that progressed to scratchiness on her
tongue. Her mother, seeing nothing unusual in her daughter’s
mouth, assumed she was having postnasal drainage from
seasonal allergies and gave her diphenhydramine. One hour
TABLE 3. Adverse Events Observed in at Least 2 Subjects
in a Randomized, Double-Blind, Placebo-Controlled Trial

















Limb injury 2 2
Back pain 2 2
Pain in extremity 2 2
Pruritus 2 2
*There were no treatment-emergent serious adverse reactions observed in this trial.
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later the girl was spitting saliva in a cup and complaining of
a tight throat and inability to swallow. The mother took her to
the ED. Initial questioning revealed there was no history of
similar events and the patient had neither insect-bite exposure
nor new medications or foods in the prior 24 hours. She had
a history of seasonal allergic rhinitis with typical symptoms,
but no history of food or drug allergies. The patient took
antihistamines as needed for seasonal allergies and a multi-
vitamin daily. She had been in the ED 2 months previously
because of intractable vomiting that began 6 hours after being
hit in the stomach by a soccer ball.
Vital signs consisted of a blood pressure of 100/66 mm Hg,
heart rate 100, respirations 20, and 90% oxygen saturation on
room air; she was afebrile. Physical examination was normal
with a few exceptions: her voice was hoarse, her head was
tilted forward, the posterior pharynx and uvula were edema-
tous, and inspiratory stridor was heard over the trachea. No
facial, tongue, lip, or neck swelling or cervical adenopathy or
tenderness were noted.
On arrival, the patient received oxygen supplementation,
IV diphenhydramine HCl 50 mg, IV methylprednisolone 60 mg,
and epinephrine (1:1000) 0.3 mL given intramuscularly. The
patient’s symptoms did not change with these maneuvers.
Laboratory evaluation included a normal complete blood
count and chemistry panel. Chest x-ray was normal, however,
soft-tissue lateral neck film revealed straightening of the cervical
spine with edema of the epiglottis and upper airway.
The mother subsequently revealed a family history of
attacks of throat swelling, episodic hand and foot swelling,
and abdominal pain. Both the mother and a maternal aunt had
been diagnosed with HAE in their teenage years. The patient
had recently been found to have C1-esterase inhibitor defi-
ciency consistent with a diagnosis of HAE, although she had
not had any apparent swelling attacks.
After the family history of HAE was revealed, the
mother’s physician was called. The child had been diagnosed
with type 1 HAE and enrolled in a clinical study for treatment of
attacks of HAE. Her laboratory results on entry to the study were
C4 4 mg/dL, C1-esterase inhibitor 8 mg/dL, and functional
C1-esterase inhibitor 22%. Open-label study drug was provided
by the physician. The patient was given 1000 units of nanofil-
tered C1-esterase inhibitor by IV infusion over 10 minutes.
Within 30 minutes, the patient was able to swallow.
In light of this potentially life-threatening laryngeal HAE
attack, the child’s physician prescribed routine prophylaxis with
C1-esterase inhibitor concentrate. Currently, the patient receives
infusions of 1000 units of nanofiltered C1-esterase inhibitor
every 3 to 4 days. She has experienced no severe HAE swelling
attacks since beginning prophylactic therapy 1 year ago.
Although diagnosing HAE may be difficult because of
variability in clinical presentation, this case illustrates the
importance of having a high level of suspicion for HAE in
patients presenting with characteristic symptoms, especially
in the presence of a positive family history.25 It is recom-
mended that symptom-free children with a positive family
history have an initial screening (including complement tests)
at the age of 6 months and again at 1 year of age.64
Patients experiencing laryngeal edema often complain
of tightness of the throat, inability to clear saliva, and dys-
phagia. Patients may also have edema of the soft palate or
tongue, making swallowing and breathing difficult.37 Because
laryngeal edema can be fatal, prompt treatment is essential.33
As seen with this patient, misdiagnosis of HAE symptoms is
common. Standard therapies for allergy-mediated angioedema
(eg, epinephrine, corticosteroids, and antihistamines) are not
effective in treating HAE symptoms because HAE manifesta-
tions are mediated by bradykinin whereas angioedema caused
by allergic reactions is mediated by histamine and other medi-
ators.9 In this case, the patient’s laryngeal edema did not respond
to standard therapies for an allergic reaction. This case also
highlights the need for patient and caregiver education about
HAE symptoms and emergency care procedures. Although the
mother was diagnosed with HAE and was aware her child had
a C1-esterase inhibitor deficiency, there were delays in obtaining
medical attention and in providing family and patient history to
medical personnel.
FIGURE 4. Quality-of-life improve-
ments: life activity items and total
score (standardized items on an 11-
point scale). All item values achieved
during C1-esterase inhibitor therapy
improved significantly compared
with danazol prophylaxis (Wilcoxon
signed rank test; P  0.001)
resulting in a significantly improved
total score for patients receiving
C1-esterase inhibitor therapy. Bold
bars in the middle of the box
represent mean values and normal
bars stand for median values.
Prospective phase  C1-esterase
inhibitor therapy; retrospective
phase  danazol therapy (repro-
duced from Kreuz et al,89 with
permission).
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Long-term prophylaxis is indicated for patients who ex-
perience frequent or severe attacks, laryngeal attacks, have
significant anxiety or poor quality of life as a result of HAE, or
have limited access to emergency medical care.37 The fact that
this patient has not experienced severe HAE swelling attacks
since beginning prophylactic therapy underscores the value of
this therapy in the management of HAE. Nevertheless, because
the clinical course of HAE demonstrates vast variability over the
lifetime of an individual patient, the need for prophylactic
therapy should be reassessed at regular intervals.
CASE 2: LONG-TERM PROPHYLAXIS WITH
ATTENUATED ANDROGEN
A 35-year-old female patient experienced periodic ep-
isodes of peripheral edema of the hands or feet with occa-
sional edema around the waist beginning at 7 years of age
(case provided by Dr Teresa Caballero, Spain). Most episodes
were accompanied by abdominal symptoms, including ab-
dominal bloating, nausea, and vomiting. Occasionally the
attacks were preceded by a skin rash consistent with serpig-
inous erythematous macules with a clear center. Family
history was negative for angioedema; she had a personal
history of seasonal rhinoconjunctivitis. The patient was ini-
tially evaluated for a rheumatic disorder and for drug allergy.
In 1996 at the age of 21, she was diagnosed with HAE
caused by C1-esterase inhibitor deficiency. Danazol 200 mg
every 8 hours was prescribed and symptoms were well
controlled. The dose of danazol was progressively reduced to
200 mg 3 days a week. In 2000, she was referred to a
comprehensive HAE center for evaluation. The patient did
not experience any secondary effects related to attenuated
androgen therapy (ie, she did not experience amenorrhea,
weight gain, hypertension, dyslipidemia, voice change, or
hirsutism). Evaluation revealed that precipitant factors in-
cluded menses, upper respiratory tract infections, and oral
contraceptives containing estrogens.
Hemogram, erythrocyte sedimentation rate (ESR), blood
biochemistry (cholesterol, triglycerides, AST, ALT, others), and
urinalysis were all within normal limits. Blood serologies were
negative for human immunodeficiency virus (HIV), hepatitis C
virus (HCV), and parvovirus. Serology testing for hepatitis B
virus (HBV) was positive for anti-HBs antibodies with negative
anticore antibodies and negative HbS antigen, which is concor-
dant with HBV postimmunization.
Results of complement studies were C4  2.68 mg/dL
(normal 14 to 47 mg/dL), C1-esterase inhibitor 4.8 mg/dL
(normal 14 to 40 mg/dL), and functional C1-esterase inhibitor
24% (normal 70 to 120%); values were normal for C3 and C1q.
Complement analysis was normal in her parents and siblings.
Genetic studies were performed in the patient and her parents,
and a mutation was confirmed in the patient, but was not
present in either of her parents.
The patient was diagnosed with HAE caused by C1-
esterase inhibitor deficiency (spontaneous mutation/de novo mu-
tation). Although her HAE symptoms had been well controlled
with danazol and she did not experience adverse effects from the
drug, the prophylaxis treatment was changed to stanozolol 2 mg
3 days a week based on our positive experience with this drug
and the evidence that it is associated with fewer adverse ef-
fects.70 Plasma-derived human C1-esterase inhibitor (Berinert,
CSL-Behring, Marburg, Germany) was recommended for at-
tacks and medication was given for home storage. The patient
was advised to increase the dose of stanozolol in the event of an
upper respiratory tract infection or other known precipitant
factors. Plasma-derived human C1-esterase inhibitor was also
recommended for short-term prophylaxis before medical or
surgical interventions.
The patient has been followed every 6 months on an
outpatient basis for the past 10 years. Her disease has been
well controlled, with 0 to 2 mild edema attacks per year.
Blood and urine analyses have been conducted every
6 months and an abdominal ultrasound has been performed
annually. Occasional transient mild hypercholesterolemia
(222 mg/dL) (normal 200 mg/dL) and occasional transitory
elevation of hepatic enzymes (ALT 48 UI/L) (normal 30
UI/L) have been detected. Other laboratory investigations
have been within normal limits. No changes have been
detected on abdominal ultrasound.
This patient is a good example of the variability of
clinical expression of HAE disease and the possibility of
controlling disease with low doses of attenuated androgens in
some patients. Although the patient had exhibited obvious
symptoms since the age of 7 years, she was not diagnosed
until 21 years of age. Although many patients with HAE have
delayed diagnoses,107 the elapsed time between initiation of
symptoms and diagnosis in this patient was 14 years, which
may be attributed to the absence of family history of HAE.
Diagnosis may be delayed in patients with de novo mutation,
which may be present in up to 25% of HAE patients, because
of the lack of family history.108
Until recently, attenuated androgen therapy was the
only approved prophylaxis treatment option for HAE in the
United States.58 This patient’s disease has been controlled
with low doses of attenuated androgen (first danazol and later
stanozolol) for more than 10 years, with a maintenance dose
as low as stanozolol 2 mg 3 days per week. Although
attenuated androgens are associated with significant adverse
effects,59 this patient has tolerated treatment well. In her case,
the only reported adverse effects that may be associated with
stanozolol were mild hypercholesterolemia and mild eleva-
tion of hepatic enzymes, both of which spontaneously nor-
malized. Attenuated androgens also provide the convenience
of oral dosing.
This case also exemplifies the need for vigilance and
thorough monitoring while on androgen therapy as outlined
by the International Consensus Algorithm for the Diagnosis,
Therapy, and Management of Hereditary Angioedema.25 Pa-
tients receiving attenuated androgen therapy should be eval-
uated every 6 months for changes in liver function, lipid
profile, complete blood count, and urinalysis. Periodic ultra-
sounds of the liver and spleen are also recommended.
CASE 3: INTERMITTENT PROPHYLAXIS
The patient is a 33-year-old female (case provided by
Dr Henriette Farkas, Hungary). At the age of 4 years the
patient developed extremity edema after minor mechanical
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trauma that resolved spontaneously within 2 days. Subse-
quently, once or twice a year the patient experienced edem-
atous episodes of several days’ duration involving the upper
or lower extremities. Edema always resolved spontaneously
and its cause could not be identified. Appendectomy was
performed at the age of 7 years, and intraoperative findings
included free peritoneal fluid and edematous intestines. At 10
years of age, the patient experienced facial edema after a
tonsillectomy. Edema was treated with antihistamines and glu-
cocorticoids and resolved slowly over 3 days. This event raised
the suspicion of HAE. Clinical findings, a positive family history
(the patient’s mother died of suffocation from laryngeal edema
at the age of 32), and the results of complement testing (C4: 0.02
g/L [normal 0.15 to 0.55 g/L]; C1-esterase inhibitor antigenic
level: 0.03 g/L [normal 0.15 to 0.3 g/L]; C1-esterase inhibitor
functional activity: 18% [normal 70 to 100%]; C1q: 118 mg/L
[normal 60 to 180 mg/L]) confirmed the diagnosis of type I
HAE. The patient was enrolled in a follow-up program with 2
prescheduled control visits each year.
At the age of 13, the frequency and severity of edematous
episodes increased. Attacks recurred on 2 or 3 occasions per
month and an abdominal attack occurred. The increased fre-
quency of attacks was attributed to the physiological hormonal
changes of puberty. A trial of prophylactic therapy with tranex-
amic acid was ineffective, and therefore, danazol 200 mg daily
was introduced. This relieved symptoms considerably, with the
number of attacks decreasing to as low as 2 to 3 extremity
attacks and 1 abdominal attack per year. The patient tolerated
pharmacotherapy well. Adverse effects included transient epi-
sodes of irregular menses and headache, but these were not
severe enough to warrant discontinuation of treatment. The dose
of danazol was reduced to 100 mg every other day.
An unplanned pregnancy occurred at the age of 23 and
danazol was discontinued. This was followed by a dramatic
increase in attack frequency; edematous episodes recurred 2
to 3 times per week and 80% of the attacks were of the
combined type (severe abdominal attack with extremity
edema). Laryngeal edema developed on a single occasion.
C1-esterase inhibitor administered during attacks was effec-
tive; it mitigated symptoms within 15 to 30 minutes. Thus,
intermittent C1-esterase inhibitor prophylaxis was introduced
in the eighth week of gestation. Administration of 500 IU
C1-esterase inhibitor twice a week achieved near-complete
elimination of symptoms, with only 1 episode of mild ex-
tremity edema that occurred after mechanical trauma. The
patient did not experience any adverse reactions to therapy.
After the 12th week of pregnancy, the dose of C1-esterase
inhibitor was reduced to 500 IU weekly and then, as the
patient had become symptom-free, C1-esterase inhibitor pro-
phylaxis was discontinued at week 15. The patient gave birth
by vaginal delivery to a healthy neonate during the 38th week
of gestation; the child has not inherited HAE. Although no
edema developed during delivery, C1-esterase inhibitor was
kept at hand. Long-term prophylaxis was not necessary dur-
ing the 2-month lactation period. Several instances of mild
subcutaneous edema and a single abdominal attack occurred;
the latter responded to acute treatment with 500 IU of
C1-esterase inhibitor. The patient remained symptom-free for
2 years after the lactation period. Subsequently, however,
increasing attack frequency and severity (with no identifiable
cause) required the reintroduction of danazol prophylaxis.
Currently, the patient is on danazol 100 mg every other day.
This case illustrates that long-term prophylaxis of HAE
does not necessarily mean uninterrupted drug therapy over a
lifetime. During regularly scheduled check-ups, the therapeu-
tic regimen can be modified: drugs may be discontinued,
others may be introduced, and dosages may be adjusted. In
this case, tranexamic acid was ineffective, and therefore,
switching to danazol was necessary. Titration to the lowest
effective dose (in this patient from the daily 200-mg initial
dose to 100 mg every other day) is recommended to avoid or
at least mitigate adverse effects.2
Precipitating factors such as stress, trauma, infection,
menstruation, and pregnancy have been reported to contribute
to the frequency of HAE attacks.3,4,9,21,23 Short-term prophy-
lactic treatment, also referred to as procedural prophylaxis, is
advised for patients with a planned exposure to a situation
that may trigger an attack, such as dental work or invasive
medical procedures.2,25 The care of pregnant women, how-
ever, is complicated by the potential adverse effects of atten-
uated androgens on the developing fetus.2 In this patient,
danazol was discontinued when she became pregnant and
attack frequency increased dramatically. Recent consensus
guidelines proposed that C1-esterase inhibitor is the safest
prophylactic agent during pregnancy.25 In this patient, inter-
mittent prophylaxis with C1-esterase inhibitor during preg-
nancy proved a safe and effective therapy. Although inter-
mittent prophylaxis of HAE is not mentioned in relevant
clinical guidelines, it may be a safe and effective treatment
modality in children64 and in cases in which the identifiable
cause of increased attack frequency and severity (such as
pregnancy in our case) cannot be eliminated.
CASE 4: OPTIMIZING THERAPY FOR HAE
The patient is a 45-year-old male welding instructor at
a technical college (case provided by Dr Douglas Johnston,
USA). His family history is positive for HAE; his father died
of a laryngeal HAE attack and his sister, nephew, and son
have HAE. The patient presented with recurrent intermittent
bouts of abdominal pain. These episodes, which began at
8 years of age, are described as crampy discomfort that lasts
for 3 to 4 days despite medications and resolve on their own.
The patient was diagnosed with HAE at 16 years of age after
being hospitalized for a severe abdominal episode. Initial
treatment was with methyltestosterone, but this was changed
to stanozolol for greater efficacy. Stanozolol was switched to
danazol 15 years ago; however, the patient began experienc-
ing more frequent swelling episodes and approximately
4 severe abdominal episodes a year while receiving danazol
200 mg daily. Triggers for the attacks include upper respira-
tory infections, alcohol, amoxicillin, pizza, and yeast rolls.
The patient continued to take danazol 200 mg daily, but
experienced recurrent swelling of the hands and feet approx-
imately 8 to 10 times per year, with each episode lasting
between 3 and 5 days. These episodes were often mild and
did not require medical attention. Laboratory values were
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C1-esterase inhibitor of 5 mg/dL, functional C1-esterase
inhibitor at 1%, C4 of 5 mg/dL, and normal AST and ALT.
An ultrasound of the right upper quadrant was notable for
3 small hepatic hemangiomata.
Long-term prophylactic therapy was changed to stano-
zolol 2 mg daily, which led to less frequent abdominal
attacks. The patient continued to have hand swelling, and
although the frequency of attacks was decreased, the patient
missed work as a result of the attacks. While taking stano-
zolol, AST and ALT increased to 48 and 71 IU/L, respec-
tively, blood pressure and low-density lipoprotein increased,
and high-density lipoprotein decreased. Therapy was changed
to C1-esterase inhibitor 1000 units twice a week. During the
past 6 months, the patient has had 2 episodes of abdominal
swelling, which were less intense than his previous episodes.
One was precipitated by trauma and the other was attributed
to eating several slices of pizza. The patient reports that when
he has forgotten to administer a dose of C1-esterase inhibitor,
he suffers from hand swelling, which functions as a reminder
to take his medication. The swelling often resolves within 1 hour
after administration of the dose. His AST and ALT are normal
(25 and 29 IU/L, respectively), and high-density lipoprotein has
increased from 31 to 39 mg/dL.
This case highlights the need for optimizing therapy for
HAE. Treatment of HAE should be individualized and based
on an assessment of the severity, frequency, and nature of the
attacks. This, in combination with the patient’s circumstances,
should guide the development of an appropriate treatment plan.
This patient experienced frequent attacks that had a negative
impact on his quality of life, making him a candidate for
long-term prophylaxis.37 Despite prophylactic therapy with
danazol, he continued to have frequent attacks. After therapy
was changed to stanozolol the frequency of the attacks
decreased; however, his attacks continued to result in work
absences. Furthermore, his laboratory tests indicated lipid
abnormalities and increased liver enzymes, which are adverse
effects associated with attenuated androgen therapy.59,62,75
Therapy was changed to C1-esterase inhibitor in an attempt to
provide a better clinical outcome and to avoid the deleterious
effects of attenuated androgen therapy. The number and
severity of his attacks have decreased with C1-esterase in-
hibitor therapy and his laboratory values have improved. This
case underscores the importance of the physician-patient
relationship in the management of HAE to optimize pharma-
cotherapy and to improve education of the patient. Although
the patient recognizes certain triggers for his attacks, he
should be reminded to avoid stimuli that may precipitate
attacks to substantially improve disease control.2 Further-
more, compliance with therapy should be emphasized be-
cause this will likely lessen the number of attacks suffered by
the patient.
SUMMARY: IMPLICATIONS FOR THE SELECTION
OF PROPHYLACTIC THERAPY FOR HAE
HAE is a serious disease that may cause life-threatening
and disabling symptoms, which can have a dramatic impact on
quality of life. Because the manifestations and severity of HAE
are highly variable and unpredictable, patients need individual-
ized care to reduce the burden of HAE on daily life. Further-
more, differences exist between European and US interventions
for HAE primarily because of differences in product availability.
On-demand therapy for attacks with C1-esterase inhibitor is
sometimes used as a patient’s sole method of treatment or it may
be used to treat breakthrough attacks in patients who are taking
long-term prophylaxis. Routine long-term prophylaxis with ei-
ther attenuated androgens or C1-esterase inhibitor has been
shown to reduce the frequency and severity of HAE attacks.
Therapy with attenuated androgens, a mainstay of treatment in
the past, has been marked by concern about potential adverse
effects. C1-esterase inhibitor works directly on the complement
and contact plasma cascades to reduce bradykinin release, which
is the primary pathologic mechanism in HAE. As our patient
cases illustrate, different approaches to long-term prophylactic
therapy can successfully provide HAE management that is
tailored to meet the needs of the individual patient.
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